These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 25824211)
1. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Rubino CM; Bhavnani SM; Moeck G; Bellibas SE; Ambrose PG Antimicrob Agents Chemother; 2015; 59(6):3365-72. PubMed ID: 25824211 [TBL] [Abstract][Full Text] [Related]
2. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W; Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Bhavnani SM; Owen JS; Loutit JS; Porter SB; Ambrose PG Diagn Microbiol Infect Dis; 2004 Oct; 50(2):95-102. PubMed ID: 15474317 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Fetterly GJ; Ong CM; Bhavnani SM; Loutit JS; Porter SB; Morello LG; Ambrose PG; Nicolau DP Antimicrob Agents Chemother; 2005 Jan; 49(1):148-52. PubMed ID: 15616289 [TBL] [Abstract][Full Text] [Related]
5. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens. Das B; Sarkar C; Schachter J Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967 [TBL] [Abstract][Full Text] [Related]
6. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains. Bouza E; Burillo A Int J Antimicrob Agents; 2010 Nov; 36(5):401-7. PubMed ID: 20729040 [TBL] [Abstract][Full Text] [Related]
14. Oritavancin, a new lipoglycopeptide antibiotic: results from a thorough QT study. Darpo B; Lee SK; Moon TE; Sills N; Mason JW J Clin Pharmacol; 2010 Aug; 50(8):895-903. PubMed ID: 20484618 [TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections. Rubino CM; Xue B; Bhavnani SM; Prince WT; Ivezic-Schoenfeld Z; Wicha WW; Ambrose PG Antimicrob Agents Chemother; 2015 Jan; 59(1):282-8. PubMed ID: 25348519 [TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of doripenem in Japanese subjects and Monte-Carlo simulation for patients with renal impairment. Matsuo Y; Ishibashi T; Kubota R; Wajima T J Infect Chemother; 2015 Feb; 21(2):123-9. PubMed ID: 25487084 [TBL] [Abstract][Full Text] [Related]
17. Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies. Corey GR; Loutit J; Moeck G; Wikler M; Dudley MN; O'Riordan W; Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358292 [TBL] [Abstract][Full Text] [Related]
18. Oritavancin: a review in acute bacterial skin and skin structure infections. Syed YY; Scott LJ Drugs; 2015 Nov; 75(16):1891-902. PubMed ID: 26464319 [TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies. Trang M; Seroogy JD; Van Wart SA; Bhavnani SM; Kim A; Gibbons JA; Ambrose PG; Rubino CM Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670433 [TBL] [Abstract][Full Text] [Related]
20. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Guskey MT; Tsuji BT Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]